Current state-of-the-art of concomitant chemoradiation in cervical carcinomas

Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic radiation has been the standard therapy for advanced disease with overall five-year survival rates of 50%. Recently, five randomized trials demonstrated a significant survival advantage for the concomitant administration of radiotherapy and cisplatin-based chemotherapy. Although the trials vary somewhat in terms of stage of disease, dose of radiation, and schedule of radiation and cisplatin, they all demonstrated a significant survival benefit for the combined approach. Congruent to these findings are results from a meta-analysis based on the data from 19 trials with 4,580 randomized patients. The absolute increase in progression-free and overall survival was 16% and 12%, respectively. Contrary to these findings is the result of the National Cancer Institute of Canada (NCCI) trial. Despite that result cisplatin-based concomitant chemoradiotherapy has become the standard treatment of locally advanced cervical cancer.

Cervical cancer; Concomitant chemoradiotherapy; Cisplatin

[1] Parker S., Tong T., Bolden S. et. al.: "Cancer Statistic". 1996, CA Cancer J. Clin., 1996, 46, S.

[2] Advances in the treatment of cervical cancer. "International Network for Cancer Treatment and Research". Belgium, 20 April, 2001 Meeting.

[3] Average years of life lost from cancer. J. Natl. Cancer Inst., 1993, 201, 2341.

[4] Coia L., Won M., Lanciano R. et al.: "The patterns of care outcome study for cancer of the uterine cancer: Results of the Second National Practice Survey". Cancer, 1990, 66, 2451.

[5] Dorr R.T., Fritz W.L.: "Cancer Chemotherapy Handbook". New York, NY, Elsevier, 1980.

[6] Keys H.M., Bundy B.N., Stehman F.B. et al.: "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IE cervical carcinoma". N. Engl. J. Med., 1999, 340, 1154.

[7] Peters W.A., Liu P.Y., Barrett R.J. et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oneal., 2000, 18, 1606.

[8] Whitney C.W., Sause W., Bundy B.N. et al.: "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study". J. Clin. Oneal., 1999, 17, 1339.

[9] Morris M., Eifel P.J., Lu J. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.

[10] Rose P.G., Bundy B.N., Watkins E.B. et al.: "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer". N. Engl. J. Med., 1999, 340, 1144.

[11] National Cancer Institute: NCI Clinical Announcement. Bethesda, M.D., United States Department of Health and Human Services, Public Health Service, National Institutes of Health, February 1999.

[12] Goldie J.H., Coldman A.J.: "A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate". Cancer Treat Rep., 1979, 63, 1727.

[13] Dewit L.: "Combined treatment of radiation and cis-diamminedichloroplatinum (II): A review of experimental and clinical data". Int. J. Radiat. Oncol. Biol. Phys., 1987, 13, 403.

[14] Douple E.B.: "Platinum-radiation interactions". NCI Monogr., 1988, 6, 315.

[15] Withers H.R., Taylor J.M.G., Maciejewski B.:'The hazard of accelerated tumor clonogen repopulation during radiotherapy". Acta Oncol., 1988, 27, 131.

[16] Perez C.A., Fox S., Lockett M.A. et al.: "Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: Analysis of two different methods". Int. J. Radiat. Oneal. Biol. Phys., 1991, 21, 885.

[17] Pederson D., Bentzen S.M., Overgaad J.: "Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix". Int..!. Radial. Oncol. Biol. Phys., 1994, 29, 941.

[18] Teshima T., Inoue T., Ikeda H. et al.: "High dose rate and low dose rate intracavitary therapy for carcinoma of the uterine cervix". Cancer, 1993, 72, 2409.

[19] Omura G.A.: "Current status of chemotherapy for cervix cancer". Oncology, 1992, 6, 27.

[20] Thigpen T., Shingleton H., Homesley H. et al.: "Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix". Cancer, 1981, 48, 899.

[21] Fu K.K., Lam K.N., Rayner P.A.: "The influence of time sequence of Cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma". Int..I. Radial. Oncol. Biol. Phys., 1985, 11, 21.

[22] Douple E.B.,R ichmond R.C.: "A review of interaction between platinum coordination complexes and ionizing radiation: Implication for cancer therapy". In: Prestayko A.W., Crooke S.T., Carter S.K. (eds.): "Cisplatin Current Status and New Developments". New York, NY, Academic Press, 1980, 125.

[23] Wong L.C., Ngan H.Y.S., Cheung A.N.Y. et al.: "Chemoradiation and adjuvant chemotherapy in cervical cancer". J. Clin. Oncol., 1999, 17, 2055.

[24] Pearcey R., Brundage M., Drouin P. et al.: "Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix"../. Clin. Oncol., 2002, 20, 966.

[25] Fyles A.W., Pintile M., Kirkbride P. et al.: "Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multipie regression analysis". Radiother. Oncol., 1995, 35, 107.

[26] Grogan M., Thomas G.M., Melamed I. et al.: "The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix". Cancer, 1999, 86, 1528.

[27] Green J.A.,K irwan J.M.,T ierney J.F. et al.: "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the utenne cervix: a systematic review and meta-analysis". Lancet, 2001, 358, 781.

[28] Vrdoljak E., Prskalo T., Frleta Ilic N. et al.: "Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma (LASCC) of the cervix uteri: results of a phase II study". Gynecol. Oncol., 2003, 88, 194 (abstr 79).

[29] Tonkin K.S., Kelland L.R., Steel G.G.: "Chemotherapy-radiation interactions in human cervix carcinoma xenografts". Br..!. Cancer, 1988, 58, 738.